Core Insights - Labcorp reported 3.33billioninrevenueforQ42024,ayear−over−yearincreaseof9.83.32 billion [1] - The EPS for the same period was 3.45,comparedto3.30 a year ago, with an EPS surprise of +1.47% against the consensus estimate of 3.40[1]RevenuePerformance−BiopharmaLaboratoryServicesgenerated767 million, exceeding the estimated 747.52million,representinga+10.42.59 billion, slightly above the estimated 2.57billion,reflectinga+10.2130.80 million, surpassing the average estimate of 123.15million[4]−AdjustedOperatingIncomeforDiagnosticsLaboratorieswas359.50 million, which fell short of the average estimate of $382.85 million [4] Stock Performance - Labcorp's shares have returned +6.7% over the past month, outperforming the Zacks S&P 500 composite's +2.1% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]